Gian Marco De Marchis1, Theresa Dankowski2, Inke R König2, Joachim Fladt2, Felix Fluri2, Henrik Gensicke2, Christian Foerch2, Oliver Findling2, Rebekka Kurmann2, Urs Fischer2, Andreas Luft2, Daniela Buhl2, Stefan T Engelter2, Philippe A Lyrer2, Mirjam Christ-Crain2, Marcel Arnold2, Mira Katan2. 1. From the Department of Neurology & Stroke Center (G.M.D.M., J.F., H.G., S.T.E., P.A.L.), Department of Internal Medicine (M.C.-C.), and Department of Clinical Research (M.C.-C.), Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, University of Basel, Switzerland; Institute of Medical Biometry and Statistics (T.D., I.R.K.), University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck; Department of Neurology (F.F.), University Hospital Würzburg; Department of Neurology (C.F.), Goethe University, Frankfurt a.M., Germany; Department of Neurology (O.F.), Cantonal Hospital Aarau; Department of Neurology (R.K., U.F., M.A.), Inselspital, University Hospital Bern; Department of Neurology (A.L., M.K.), University Hospital Zurich; Department of Laboratory Medicine (D.B.), Kantonsspital, Lucerne; and Neurorehabilitation Unit (S.T.E.), University Center for Medicine of Aging and Rehabilitation, Felix Platter Hospital, University of Basel, Switzerland. Gian.demarchis@usb.ch. 2. From the Department of Neurology & Stroke Center (G.M.D.M., J.F., H.G., S.T.E., P.A.L.), Department of Internal Medicine (M.C.-C.), and Department of Clinical Research (M.C.-C.), Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, University of Basel, Switzerland; Institute of Medical Biometry and Statistics (T.D., I.R.K.), University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck; Department of Neurology (F.F.), University Hospital Würzburg; Department of Neurology (C.F.), Goethe University, Frankfurt a.M., Germany; Department of Neurology (O.F.), Cantonal Hospital Aarau; Department of Neurology (R.K., U.F., M.A.), Inselspital, University Hospital Bern; Department of Neurology (A.L., M.K.), University Hospital Zurich; Department of Laboratory Medicine (D.B.), Kantonsspital, Lucerne; and Neurorehabilitation Unit (S.T.E.), University Center for Medicine of Aging and Rehabilitation, Felix Platter Hospital, University of Basel, Switzerland.
Abstract
OBJECTIVES: To derive and externally validate a copeptin-based parsimonious score to predict unfavorable outcome 3 months after an acute ischemic stroke (AIS). METHODS: The derivation cohort consisted of patients with AIS enrolled prospectively at the University Hospital Basel, Switzerland. The validation cohort was prospectively enrolled after the derivation cohort at the University Hospital of Bern and University Hospital Basel, Switzerland, as well as Frankfurt a.M., Germany. The score components were copeptin levels, age, NIH Stroke Scale, and recanalization therapy (CoRisk score). Copeptin levels were measured in plasma drawn within 24 hours of AIS and before any recanalization therapy. The primary outcome of disability and death at 3 months was defined as modified Rankin Scale score of 3 to 6. RESULTS: Overall, 1,102 patients were included in the analysis; the derivation cohort contributed 319 patients, and the validation cohort contributed 783. An unfavorable outcome was observed among 436 patients (40%). For the 3-month prediction of disability and death, the CoRisk score was well calibrated in the validation cohort, for which the area under the receiver operating characteristic curve was 0.819 (95% confidence interval [CI] 0.787-0.849). The calibrated CoRisk score correctly classified 75% of patients (95% CI 72-78). The net reclassification index between the calibrated CoRisk scores with and without copeptin was 46% (95% CI 32-60). CONCLUSIONS: The biomarker-based CoRisk score for the prediction of disability and death was externally validated, was well calibrated, and performed better than the same score without copeptin. CLINICALTRIALSGOV IDENTIFIER: NCT00390962 (derivation cohort) and NCT00878813 (validation cohort).
OBJECTIVES: To derive and externally validate a copeptin-based parsimonious score to predict unfavorable outcome 3 months after an acute ischemic stroke (AIS). METHODS: The derivation cohort consisted of patients with AIS enrolled prospectively at the University Hospital Basel, Switzerland. The validation cohort was prospectively enrolled after the derivation cohort at the University Hospital of Bern and University Hospital Basel, Switzerland, as well as Frankfurt a.M., Germany. The score components were copeptin levels, age, NIH Stroke Scale, and recanalization therapy (CoRisk score). Copeptin levels were measured in plasma drawn within 24 hours of AIS and before any recanalization therapy. The primary outcome of disability and death at 3 months was defined as modified Rankin Scale score of 3 to 6. RESULTS: Overall, 1,102 patients were included in the analysis; the derivation cohort contributed 319 patients, and the validation cohort contributed 783. An unfavorable outcome was observed among 436 patients (40%). For the 3-month prediction of disability and death, the CoRisk score was well calibrated in the validation cohort, for which the area under the receiver operating characteristic curve was 0.819 (95% confidence interval [CI] 0.787-0.849). The calibrated CoRisk score correctly classified 75% of patients (95% CI 72-78). The net reclassification index between the calibrated CoRisk scores with and without copeptin was 46% (95% CI 32-60). CONCLUSIONS: The biomarker-based CoRisk score for the prediction of disability and death was externally validated, was well calibrated, and performed better than the same score without copeptin. CLINICALTRIALSGOV IDENTIFIER: NCT00390962 (derivation cohort) and NCT00878813 (validation cohort).
Authors: Ana Lima Silva; Ana Sofia Pessoa; Renato Nogueira; José Manuel Araújo; José Nuno Alves; João Pinho; Carla Ferreira Journal: Neurol Sci Date: 2019-11-11 Impact factor: 3.307
Authors: Benjamin Hotter; Sarah Hoffmann; Lena Ulm; Joan Montaner; Alejandro Bustamante; Christian Meisel; Andreas Meisel Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-02-25